Inhibition of extrinsic hemostasis activation by low-molecular-weight heparin

Blood Coagulation and Fibrinolysis

Volumn 17, Issue 8, 2006, Pages 633-637

  Stief, Thomas W ^a,b  

^a UNIVERSITY HOSPITAL GIESSEN   (Germany)

^b UNIVERSITY HOSPITAL MARBURG   (Germany)

Author keywords

Dalteparin; Extrinsic coagulation activity assay; Hemostasis; Heparin; Low molecular weight heparin; Pentosanpolysulfate; Thrombin

Indexed keywords

ANTICOAGULANT AGENT; ARGININE; CITRIC ACID; DALTEPARIN; HEPARIN; HUMAN ALBUMIN; LOW MOLECULAR WEIGHT HEPARIN; PENTOSAN POLYSULFATE; POLYSTYRENE; THROMBIN; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR;

ANTICOAGULATION; ARTICLE; BLOOD CLOTTING; BLOOD CLOTTING TIME; BLOOD SAMPLING; CALIBRATOR; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DRUG EFFICACY; HEMOSTASIS; HUMAN; IC 50; INCUBATION TEMPERATURE; INCUBATION TIME; PLASMA; PRIORITY JOURNAL; PROPHYLAXIS; REACTION TIME; ROOM TEMPERATURE; THROMBIN TIME;

BLOOD COAGULATION; BLOOD COAGULATION TESTS; FIBRINOLYSIS; FIBRINOLYTIC AGENTS; HEMOSTASIS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; REFERENCE VALUES; THROMBIN;

EID: 33751022836     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mbc.0000252596.79282.5d     Document Type: Article

References (36)

1. Kitchen S. Problems in laboratory monitoring of heparin dosage. Br J Haematol 2000; 111:397-406.
2. Fareed J, Ma Q, Florian M, Maddineni J, Iqbal O, Hoppensteadt D, Bick RL. Differentiation of low-molecular-weight heparins: impact on the future of the management of thrombosis. Semin Thromb Hemost 2004; 30 (Suppl 1): 89-104.
3. Stief, TW, Wieczerzak A, Renz H. The extrinsic coagulation activity assay. Clin Appl Thromb Hemost 2006; in press.
4. Denson KWE, Bonnar J. The measurement of heparin: a method based on the potentiation of anti factor Xa. Thromb Diath Haemorrh 1973; 30:471-479.
5. Teien AN, Lie M, Abildgaard U. Assay of heparin in plasma using a chromogenic substrate for activated factor X. Thromb Res 1976; 8: 413-416.
6. Tobu M, Iqbal O, Hoppensteadt D, Neville B, Messmore HL, Fareed J. Anti-Xa and anti-IIa drugs alter international normalized ratio measurements: potential problems in the monitoring of oral anticoagulants. Clin Appl Thromb Hemost 2004; 10:301-309.
7. Alhenc-Gelas M, Jestin-Le Gueinic C, Vitoux JF, Kher A, Aiach M, Fiessinger JN. Adjusted versus fixed doses of the low-molecular-weight heparin fragmin in the treatment of deep vein thrombosis. Fragmin-Study Group. Thromb Haemost 1994; 71:698-702.
8. Laposata M, Green D, Van Cott EM, Barrowcliffe TW, Goodnight SH, Sosolik RC. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: the clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban. Arch Pathol Lab Med 1998; 122: 799-807.
9. Levine MN, Raskob G, Beyth RJ, Kearon C, Schulman S. Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (3 Suppl): 287S-310S.
10. Wolak A, Ayzenberg Y, Cafri C, Gilutz H, Ilia R, Zahger D. Can enoxaparin safely replace unfractionated heparin during coronary intervention in acute coronary syndromes? Int J Cardiol 2004; 96:151-155.
11. Montalescot G, Collet JP, Tanguy ML, Ankri A, Payot L, Dumaine R, et al. Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin. Circulation 2004; 110: 392-398.
12. Holzheimer RG. Low-molecular-weight heparin (LMWH) in the treatment of thrombosis. Eur J Med Res 2004; 9:225-239.
13. Buller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, et al., Matisse Investigators. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med 2004; 140:867-873.
14. Wolozinsky M, Yavin YY, Cohen AT. Pharmacological prevention of venous thromboemblism medical patients at risk. Am J Cardiovasc Drugs 2005; 5: 409-415.
15. Agnelli G, Bergqvist D, Cohen AT, Gallus AS, Gent M, PEGASUS investigators. Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. Br J Surg 2005; 92: 1212-1220.
16. Bergqvist D. Low-molecular-weight heparin for the prevention of postoperative venous thromboembolism after abdominal surgery: a review. Curr Opin Pulmon Med 2005; 11:392-397.
17. DeLoughery TG. Venous thromboembolism in the ICU and reversal of bleeding on anticoagulants. Crit Care Clin 2005; 21:497-512.
18. Kamphuisen PW, Agnelli G, Sebastianelli M. Prevention of venous thromboembolism after acute ischemic stroke. J Thromb Haemost 2005; 3: 1187-1194.
19. Meurin P, Tabet JY, Weber H, Renaud N, Ben Driss A. Low-molecular-weight heparin as a bridging anticoagulant early after mechanical heart valve replacement. Circulation 2006; 113:564-569.
20. Dinwoodey DL, Ansell JE. Heparins, low-molecular-weight heparins, and pentasaccharides. Clin Geriatr Med 2006; 22:1-15.
21. Ellis MH, Hadari R, Tchuvrero N, Shapira S, Kovlenko I, Kozmiakova M, et al. Hemorrhagic complications in patients treated with anticoagulant doses of a low molecular weight heparin (enoxaparin) in routine hospital practice. Clin Appl Thromb Hemost 2006; 12:199-204.
22. Lim W, Dentali F, Eikelboom JW, Crowther MA. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med 2006; 144:673-684.
23. Weinsheimer RL, Libby E, Howdieshell TR. Life-threatening abdominal wall hematoma in a chronic renal failure patient after a single dose of enoxaparin. Am Surg 2005; 71:132-134.
24. Ernits M, Mohan PS, Fares LG 2nd, Hardy H 3rd. A retroperitoneal bleed induced by enoxaparin therapy. Am Surg 2005; 71:430-433.
25. Malik A, Capling R, Bastani B. Enoxaparin-associated retroperitoneal bleeding in two patients with renal insufficiency. Pharmacotherapy 2005; 25:769-772.
26. Quiles J, Avanzas P, Bueno H. Fatal retroperitoneal haemorrhage associated with enoxaparin and impaired renal function. Int J Cardiol 2005; 98:523-524.
27. Gaiser RR, Berkowitz DH, Chou D. Epidural blood patch in a patient taking enoxaparin. Clin Anesth 2004; 16:386-388.
28. Ferguson JJ, Califf RM, Antman EM, Cohen M, Grines CL, Goodman S, et al., SYNERGY Trial Investigators. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 2004; 292:45-54.
29. Lim W, Cook DJ, Crowther MA. Safety and efficacy of low molecular weight heparins for hemodialysis in patients with end-stage renal failure: a meta-analysis of randomized trials. J Am Soc Nephrol 2004; 15:3192-3206.
30. Siguret V, Pautas E, Gouin I. Low molecular weight heparin treatment in elderly subjects with or without renal insufficiency: new insights between June 2002 and March 2004. Curr Opin Pulmon Med 2004; 10:366-370.
31. Sanson BJ, Lensing AW, Prins MH, Ginsberg JS, Barkagan ZS, Lavenne-Pardonge E, et al. Safety of low-molecular-weight heparin in pregnancy: a systematic review. Thromb Haemost 1999; 81:668-672.
32. Greer IA, Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood 2005; 106:401-407.
33. De Carolis S, Ferrazzani S, De Stefano V, Garofalo S, Fatigante G, Rossi E, et al. Inherited thrombophilia: treatment during pregnancy. Fetal Diagn Ther 2006; 21:281-286.
34. Al-Yaseen E, Wells PS, Anderson J, Martin J, Kovacs MJ. The safety of dosing dalteparin based on actual body weight for the treatment of acute venous thromboembolism in obese patients. J Thromb Haemost 2005; 3:100-102.
35. Michaels LA, Gurian M, Hegyi T, Drachtman RA. Low molecular weight heparin in the treatment of venous and arterial thromboses in the premature infant. Pediatrics 2004; 114:703-707.
36. al Dieri R, Alban S, Beguin S, Hemker W. Thrombin generation for the control of heparin treatment, comparison with the activated partial thromboplastin time. J Thromb Haemost 2004; 2:1395-1401.